glp-1 compound podcast Hub: Support, Community, and Weight Loss How to get every last

Recent studies have raised concerns about a higher risk of gastroparesis in GLP-1 medication users

Critical limitations include: Heterogeneity : Different strains, doses, and formulations make comparisons difficult Small effect sizes : Weight changes are typically modest and may not be clinically significant Short duration : Most studies last 12 weeks or less, providing no data on sustained effects Publication bias : Negative studies may be underreported There is no high-quality evidence that probiotic supplements can replicate the substantial weight loss achieved with prescription medications like semaglutide or tirzepatide

Resources for patients and families 1

Published September 2019

Conversely, some case reports for exenatide 181 and semaglutide 182 described onset or relapse of depressive symptoms, which resolved when the GLP-1RAs were stopped 181,182 and recurred on medication rechallenge 181